Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?

Labrador‐Horrillo, Moisés; Selva-O’Callaghan, Albert

doi:10.3899/jrheum.180007

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AIDs may cause chronic inflammation and increase the risk of carcinogenesis ( 9 – 12 ). Cancer can also increase the risk of AIDs ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

“…Cancer can also increase the risk of AIDs ( 13 ). The incidence of AIDs in lung cancer patients was reported to be as high as 14% to 25% ( 8 ), and some cancers show clinical features similar to AIDs ( 9 , 14 ). Due to a large number of cancer patients with preexisting AID, the safety and efficacy of ICIs in these patients deserve more attention.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

2021

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment. Because of dysregulated activation of the immune system, patients with autoimmune disease (AID) are usually excluded from ICI clinical trials. Due to a large number of cancer patients with preexisting AID, the safety and efficacy of ICIs in these patients deserve more attention. This review summarizes and analyzes the data regarding ICI therapy in cancer patients with preexisting AID from 17 published studies. Available data suggests that the efficacy of ICIs in AID patients is comparable to that in the general population, and the incidence of immune-related adverse events (irAEs) is higher but still manageable. It is recommended to administer ICIs with close monitoring of irAEs in patients with a possibly high benefit-risk ratio after a multidisciplinary discussion based on the patient’s AID category and severity, the patient’s tumor type and prognosis, alternative treatment options, and the patient’s intention. Besides, the prevention and management of irAEs in AID patients have been discussed.

show abstract

“…AIDs may cause chronic inflammation and increase the risk of carcinogenesis ( 9 – 12 ). Cancer can also increase the risk of AIDs ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

2021

View full text Add to dashboard Cite

show abstract

“…Chen et al [24] found patients with DM with cancer had elevated sPD-L1 values, especially in those with treatment-naïve cancer (in DM). So, Labrador-Horrillo et al [25] combined the data from the two results and concluded that the combination of TIF1-γ antibody and sPD-L1 could be a good option for cancer detection in this population, but it needs be confirmed in more clinical experiments, so that the related therapy could be conduct. Moreover, the serum ferritin level maybe correlated with the malignancy and disease activity, prior to chest radiography for monitoring clinical status [26].…”

Section: Tumor Occurrencementioning

confidence: 99%

Rapidly Progressive Interstitial Lung Disease Originating from Clinically Amyopathic Dermatomyositis Associated with Positive Anti-MDA 5 Antibody: a Case Report and Literature Review

Huang

Mao

2019

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Clinically amyopathic dermatomyositis (CADM) is a rare auto-immune disease, which discriminates from classical dermatomyositis; it lacks typical muscle weakness, but has a high risk of developing rapid progressive interstitial lung disease (RP-ILD), malignancies, and other fatal complications, so it is easy to cause misdiagnosis and high mortality. To attract more attention and arouse more understanding, we cover and summarize our clinical findings. Here, we reported a male patient, who rapidly progressed to serious respiratory failure despite an aggressive treatment, a combination of methylprednisolone, cyclosporine, acetylcysteine, and intravenous immunoglobulin. He suffered from CADM with positive anti-melanoma differentiation-associated gene-5 (MDA 5) antibody. CADM, as a special phenotype of DM/PM (dermatomyositis/polymyositis), is usually rapidly progressive and fatal, which requires further investigation into specific pathogenesis and more effective diagnosis as well as treatment measures. Due to the severity and rarity, we simultaneously performed a review of recent literature to provide more theoretical references for clinicians in diagnosis and treatment and finally improve the survival rate of these patients.

show abstract

Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?

Cited by 2 publications

References 12 publications

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

Rapidly Progressive Interstitial Lung Disease Originating from Clinically Amyopathic Dermatomyositis Associated with Positive Anti-MDA 5 Antibody: a Case Report and Literature Review

Contact Info

Product

Resources

About